001065343 Panoramica delle azioni Edwards Lifesciences Corporation fornisce prodotti e tecnologie per le cardiopatie strutturali e per il monitoraggio delle cure critiche negli Stati Uniti, in Europa, in Giappone e a livello internazionale. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Edwards Lifesciences Corporation Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Edwards Lifesciences Prezzi storici delle azioni Prezzo attuale dell'azione US$65.79 Massimo di 52 settimane US$0 Minimo di 52 settimane US$0 Beta 1.11 Variazione di 1 mese 0% Variazione a 3 mesi 12.52% Variazione di 1 anno n/a Variazione a 3 anni -55.02% Variazione a 5 anni 8.56% Variazione dall'IPO 153.04%
Notizie e aggiornamenti recenti
Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data Nov 26
Third quarter 2024 earnings released: EPS: US$0.61 (vs US$0.55 in 3Q 2023) Nov 08
Edwards Lifesciences Corporation Presents Data at TCT Reinforce Commitment to Structural Heart Innovation Nov 02
TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation Oct 30
Edwards Lifesciences Announces Results from the EARLY TAVR Trial Oct 29
Edwards Lifesciences Corporation Provides Earnings Guidance for the Fourth Quarter and Reiterates Sales Guidance for the Full Year 2024 Oct 25 Vedi altri aggiornamenti
Edwards’ SAPIEN 3 Ultra RESILIA Valve Demonstrates Continued Excellent Outcomes for Patients in Real World Data Nov 26
Third quarter 2024 earnings released: EPS: US$0.61 (vs US$0.55 in 3Q 2023) Nov 08
Edwards Lifesciences Corporation Presents Data at TCT Reinforce Commitment to Structural Heart Innovation Nov 02
TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation Oct 30
Edwards Lifesciences Announces Results from the EARLY TAVR Trial Oct 29
Edwards Lifesciences Corporation Provides Earnings Guidance for the Fourth Quarter and Reiterates Sales Guidance for the Full Year 2024 Oct 25
Edwards Lifesciences Corporation to Report Q3, 2024 Results on Oct 24, 2024 Oct 17
Robbins Geller Rudman & Dowd LLP Updates on Class Action Lawsuit Against Edwards Lifesciences Corporation Oct 15
Edwards Launches SAPIEN 3 With Alterra Prestent in Europe for Transcatheter Pulmonic Valve Implantation Sep 17 Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW). Sep 04
Edwards Lifesciences Corporation Provides Earnings Guidance for the Third Quarter of 2024
Edwards Lifesciences Corporation (NYSE:EW) agreed to acquire the remaining unknown majority stake in Innovalve Bio Medical Ltd. for $300 million. Jul 15
Edwards Lifesciences Announces Results from Analysis of Data from Partner Trials Examining Outcomes of Transcatheter Aortic Valve Replacement Patients with Small Annulus Jun 06
Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion. Jun 05
Edwards Lifesciences Corporation Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability May 09 Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024
Edwards Lifesciences Corporation to Report Q1, 2024 Results on Apr 25, 2024 Apr 20
Edwards Lifesciences Announces the Release of Data from the Hudle Study Apr 09
Insufficient new directors Apr 06
Edwards Lifesciences Corporation, Annual General Meeting, May 07, 2024 Mar 27
Edwards Lifesciences Announces Large, Real-World Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR Mar 12
Investor sentiment improves as stock rises 25% Mar 06
Insufficient new directors Mar 06
Edwards Lifesciences Corporation Provides Earnings Guidance for the First Quarter and Full Year 2024 Feb 07
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve Feb 02 Edwards Lifesciences Corporation to Report Q4, 2023 Results on Feb 06, 2024 Jan 31
Insufficient new directors Jan 08
Edwards Lifesciences Corporation Reaffirms Earnings Guidance for the Year 2023 and Provides Earnings Guidance for the Full Year 2024 Dec 08
Edwards Lifesciences Corporation (NYSE:EW) announces an Equity Buyback for $1,000 million worth of its shares. Dec 07
Clasp IID One-Year Data Confirm Safety and Efficacy of Edwards Pascal System for Degenerative Mitral Regurgitation Oct 29 Edwards Lifesciences Corporation Provides Earnings Guidance for Full Year 2023 and Fourth Quarter of 2023
Edwards Lifesciences Corporation's Evoque Tricuspid Valve Replacement System Receives CE Mark Oct 20
Edwards Lifesciences Corporation to Report Q3, 2023 Results on Oct 25, 2023 Oct 19
Edwards Lifesciences Corporation Announces the Results of the Eu-Hyprotect Registry Aug 15
Insufficient new directors Aug 11 Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023 Jul 28
Edwards Lifesciences Corporation Provides Sales Guidance for the Full Year 2023 Jul 27
Edwards Lifesciences Announces Results of the EU-HYPROTECT Registry Jun 09
Edwards' Aortic Valve with Resilia Tissue Shows Favorable Durability, Safety and Efficacy Outcomes in Seven Year Data May 18
First quarter 2023 earnings released: EPS: US$0.56 (vs US$0.60 in 1Q 2022) Apr 28
Edwards Lifesciences Corporation to Report Q4, 2022 Results on Jan 31, 2023 Jan 25
Edwards Lifesciences Corporation Provides Earnings Guidance for the Full Year 2023 Jan 12 Edwards Lifesciences Corporation, Annual General Meeting, May 11, 2023
Edwards Lifesciences Corporation Announces One-Year Data on Transfemoral Transcatheter Tricuspid Valve Replacement Nov 28
Edwards Lifesciences Corporation to Report Q3, 2022 Results on Oct 27, 2022 Oct 21
Edwards Lifesciences Corporation Announces Results from CLASP IID Sep 20
Edwards Lifesciences Corporation's Transcatheter Edge-To-Edge Repair Receives FDA Approval Sep 16
Edwards Lifesciences Corporation Launches SAPIEN 3 Ultra Resilia Valve Following FDA Approval Sep 13 Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year of 2022
Edwards Lifesciences Corporation to Report Q2, 2022 Results on Jul 28, 2022 Jul 22
Investor sentiment deteriorated over the past week Jun 20
Edwards Lifesciences Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2022 Apr 27
Edwards Lifesciences Corporation to Report Q1, 2022 Results on Apr 26, 2022 Apr 20
Edwards Lifesciences Corporation's MITRIS RESILIA Valve Receives FDA Approval for Mitral Replacement Surgeries Apr 01
Investor sentiment deteriorated over the past week Mar 29
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Jan 27
Edwards Lifesciences Provides Earnings Guidance for the First Quarter and Full Year of 2022 Jan 27
Edwards Lifesciences Corporation Receives FDA Approval for SAPIEN 3 with Alterra Prestent for Transcatheter Pulmonic Valve Replacement Dec 21
Edwards Lifesciences Corporation Provides Sales Guidance for Fiscal 2022 Dec 09
Independent Director recently bought CHF158k worth of stock Nov 30
Third quarter 2021 earnings released: EPS US$0.55 (vs US$0.52 in 3Q 2020) Oct 28
Second quarter 2021 earnings released: EPS US$0.79 (vs US$0.20 loss in 2Q 2020) Jul 31
Edwards Lifesciences Announces Clinical and Economic Results from 3M Transcatheter Aortic Valve Replacement Economic Study and the Partner 3 Bicuspid Registry for SAPIEN 3 TAVR Study Jul 25
Edwards Lifesciences Receives U.S. Food and Drug Administration Clearance for Hypotension Prediction Index Software for Noninvasive Acumen IQ Cuff Jun 02 Edwards Lifesciences Corporation Presents Clinical Results from Transcatheter Mitral and Tricuspid Programs as Part of the Late-Breaking Clinical Trials at EuroPCR 2021
Independent Director has left the company May 10
Edwards Lifesciences Corporation (NYSE:EW) announces an Equity Buyback for $1,000 million worth of its shares. May 06
VP & Corporate Controller recently sold CHF1.1m worth of stock Apr 25
First quarter 2021 earnings released: EPS US$0.54 (vs US$0.50 in 1Q 2020) Apr 24
Edwards Lifesciences Corporation Provides Earnings Guidance for the Full Year 2021 Apr 23
Revenue beats expectations Feb 14
Full year 2020 earnings released: EPS US$1.32 (vs US$1.68 in FY 2019) Feb 14
Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years Feb 01
Full year 2020 earnings released: EPS US$1.32 (vs US$1.68 in FY 2019) Jan 29
Revenue beats expectations Jan 29
Edwards Lifesciences Corporation to Report Q4, 2020 Results on Jan 27, 2021 Jan 14
Edwards SAPIEN 3 TAVI Receives Expanded Approval in Canada Dec 20
Third quarter earnings released Oct 22
Third-quarter earnings released: Revenue beats expectations Oct 22
Edwards Lifesciences Corporation to Report Q3, 2020 Results on Oct 21, 2020 Oct 08 Sangamo BioSciences, Inc. has entered into a definitive asset purchase agreement to acquire angiogenesis program from and Edwards Lifesciences Corporation for $7.5 million.
Insider recently sold CHF548.3k worth of stock Sep 03 Rendimenti per gli azionisti 001065343 CH Medical Equipment CH Mercato 7D 0% 1.8% 2.1% 1Y n/a 14.3% 10.1%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: Dati insufficienti per determinare come si è comportato 001065343 rispetto al settore Swiss Medical Equipment.
Rendimento vs Mercato: Dati insufficienti per determinare la performance di 001065343 rispetto al mercato Swiss.
Volatilità dei prezzi Is 001065343's price volatile compared to industry and market? 001065343 volatility 001065343 Average Weekly Movement n/a Medical Equipment Industry Average Movement 4.0% Market Average Movement 3.5% 10% most volatile stocks in CH Market 8.4% 10% least volatile stocks in CH Market 1.6%
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di 001065343 è stato volatile rispetto al mercato Swiss.
Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di 001065343 nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1958 19,800 Bernard Zovighian www.edwards.com
Edwards Lifesciences Corporation fornisce prodotti e tecnologie per le malattie cardiache strutturali e per il monitoraggio delle cure critiche negli Stati Uniti, in Europa, in Giappone e a livello internazionale. L'azienda offre prodotti transcatetere per la sostituzione delle valvole cardiache aortiche in modo minimamente invasivo, con il sistema di valvole Edwards SAPIEN, e prodotti transcatetere per la riparazione e la sostituzione delle valvole cardiache per il trattamento delle patologie della valvola mitrale e tricuspide, con i nomi PASCAL PRECISION e Cardioband. L'azienda fornisce anche soluzioni chirurgiche strutturali per il cuore, come la valvola chirurgica aortica con il nome INSPIRIS; la valvola aortica INSPIRIS RESILLA, che offre la tecnologia RESILIA tissue e VFit; KONECT RESILIA, un condotto preassemblato per valvole tissutali per procedure combinate complesse; e la valvola MITRIS RESILIA.
Mostra di più Edwards Lifesciences Corporation Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Edwards Lifesciences con la sua capitalizzazione di mercato? 001065343 statistiche fondamentali Capitalizzazione di mercato CHF 38.92b Guadagni(TTM ) CHF 1.43b Ricavi(TTM ) CHF 5.75b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 001065343 Conto economico (TTM ) Ricavi US$6.31b Costo del fatturato US$1.48b Profitto lordo US$4.84b Altre spese US$3.27b Guadagni US$1.57b
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
Feb 11, 2025
Utile per azione (EPS) 2.66 Margine lordo 76.60% Margine di profitto netto 24.82% Rapporto debito/patrimonio netto 6.2%
Come si è comportato 001065343 nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/02/02 04:09 Prezzo dell'azione a fine giornata 2024/12/20 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Edwards Lifesciences Corporation è coperta da 74 analisti. 33 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione James Francis Mainwaring Atlantic Equities LLP David Rescott Baird Ishan Majumdar Baptista Research
Mostra 71 altri analisti 
